
Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic 7-ketocholesterol (7KC) inside macrophages
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address
This month, a group of researchers published an annual report on the clinical trials that are testing drugs for Alzheimer’s disease. Overall, they reported an
We are super excited to share with you that today we released AI4L – “AI for Practical Longevity”, an open-source system that enables anyone to
A new study suggests that GLP-1 receptor agonists do not affect muscle mass any more than weight loss caused by caloric restriction, and this appears
Dr. Junyue Cao is a professor at the Rockefeller University, and his lab develops ultra-high-throughput single-cell technologies and applies them to the biology of aging.
In Aging Cell, researchers have elucidated the relationship between intestinal aging and age-related changes to the gut microbiome. Two interdependent biologies The human gut works
In a new study, the popular supplement creatine seemed to add to some of the beneficial effects of power training [1]. Trying the combination in
A new study has pit an advanced large language model against human physicians in tasks involving complex reasoning, treatment recommendations, and messy real-world patient records
The Longevity Investor Network (LIN) was created to help bridge the gap between promising longevity startups and the investors capable of helping them scale. Through
Aging is a multifaceted topic, and it’s becoming more and more clear that the only way to deal with it is piece by piece. Here’s
A perspective published in Aging Cell details the replacement-based approaches being investigated by several research organizations. Repair versus replacement This perspective begins by noting the
A recent study found an association between longer and more frequent daytime napping and higher mortality risk. The authors suggest using napping frequency and duration
A new study calls for caution in using the well-known senolytic treatment of dasatinib and quercetin (D+Q), showing that it causes damage in certain regions